The ability to quantify and continuously monitor autoregulation has tremendous implication on traumatic brain injury (TBI) and neurocritical care management. Certain key clinical scores such as Shock Index (SI), Pressure Reactivity Index (PRx) and Cerebral Perfusion Pressure (CPP) are all well understood and clinically validated measures which have been proven to be very useful in assessing and monitoring TBI patient’s status.
However, during rapidly evolving critical illnesses, accurately computing and integrating all these measures from different sources of physiological data can not only be onerous and distracting to the caregivers, but it can also be impossible.
Dr. Belle and his team developed Barreleye© as a clinical decision support system that continuously computes and graphically displays current values and past trends of these useful indices in real-time, thereby saving time and improving the clinician’s ability to quickly assess the current and future status of their patients.
Barreleye also combines these clinical measures with the novel Analytic for Hemodynamic Instability (AHI©) for monitoring patient status and predicting impending hemodynamic distress, which if undetected could potentially result in secondary brain injury or complications. Having these variables available along with traditional vital signs and ICP measurements will assist clinicians in deploying precision therapies prior to the onset of irreversible instability and injury, especially during the critical hours of care.
There are currently no tools capable of visualizing physiological trends or predicting when a patient will "crash." This means that caregivers can only react to a rapid decline in patient condition instead of intervening beforehand. While there are multiple clinical scores that can shed light on a patient's status, data collection is sporadic at best and is difficult to analyze manually.
Barreleye collects physiological data from various monitors and calculates clinically-relevant measures such as Shock Index and Pressure Reactivity Index to gauge patient trajectory and predict potential adverse events. This non-invasive technology integrates with existing monitors and systems, and can calculate hemodynamic trends to reduce the risk of secondary brain insult.
The team worked with the University of Michigan Office of Tech Transfer and our Commercialization Coach to bring the product to market. Barreleye has been licensed to Trove Analytics, Inc., based in downtown Ann Arbor, Michigan.